In different types of cancer, the unique correlation between TP53 mutation and anti-tumor immunity is the result of the combined effect of TMB and tumor aneuploidy level changes caused by TP53 mutation (28), and in TNBC, patients with TP53 mutations show good immunotherapy response characteristics and thus such mutations may be suitable biomarkers (29). The gene discussed is TP53; the disease is cancer.